Showing results (21-30 of 152) with videos related to
Sort By:
Pageof 16
Lancet (London, England)|June 3, 2014
Systemic lupus erythematosusLarissa Lisnevskaia, Grainne Murphy, David IsenbergRheumatology (Oxford, England)|October 25, 2014
Biologic treatment in Sjögren's syndromePablo Ruiz Sada, David Isenberg, Coziana CiurtinClinical and Experimental Rheumatology|June 26, 2010
Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of 3 cases and review of the literatureAna Filipa Mourão, Malcolm Rustin, David IsenbergSarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|December 12, 2007
Gastrointestinal sarcoidosis. A reviewMatthew Adler, Andrew Burroughs, Huw BeynonLupus Science & Medicine|March 1, 2017
The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectivenessBorja Gracia-Tello, Amara Ezeonyeji, David IsenbergExpert Opinion on Drug Safety|May 10, 2016
The safety of pharmacological treatment options for lupus nephritisAlba Velo-García, Eleana Ntatsaki, David IsenbergBest Practice & Research. Clinical Rheumatology|September 10, 2005
Imaging in CNS lupusPamela L Peterson, John S Axford, David IsenbergSeminars in Thrombosis and Hemostasis|February 15, 2017
Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid SyndromeHannah Cohen, Maria Efthymiou, Carolyn Gates, et al.Thrombosis Research|January 23, 2021
Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and managementZara Sayar, Rachel Moll, David Isenberg, et al.Arthritis Research & Therapy|April 10, 2013
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study designVenkat Reddy, David Jayne, David Close, et al.Pageof 16